Tacrolimus Ophthalmic, Pallimed Solutions Pharmacy, Woburn, MA
Published August 21, 2013 · Recall initiated: March 25, 2013
Summary
FDA records drug Class II recall D-875-2013, published August 21, 2013 and initiated March 25, 2013. Recalling firm: Pallimed Solutions; Status: Terminated; Lot: All lots within expiry. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Lack of Assurance of Sterility; FDA inspectional findings resulted in concerns associated with quality control procedures that impacted sterility assurance
What to do
Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Pallimed Solutions
- Distributor
- Nationwide
- Lot
- All lots within expiry
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAVancomycin Ophthalmic PF, compounded by Pallimed Solutions Pharmacy, Wobrun, MAAugust 21, 2013
- FDAAlprostadil IN NS Injection, compounded by Pallimed Solutions Pharmacy, Woburn, MAAugust 21, 2013
- FDAGentamicin Sulfate Irrigation, compounded by Pallimed Solutions Pharmacy, Woburn, MAAugust 21, 2013
- FDAHCG Chorionic Gonadotropin, compounded by Pallimed Solutions Pharmacy, Woburn, MAAugust 21, 2013
- FDAQuadmix Injection, compounded by Pallimed Solutions Pharmacy, Woburn, MAAugust 21, 2013
- FDATestosterone Cypionate/Testosterone Enanthate Injection, compounded by Pallimed Solutions Pharmacy, Woburn, MAAugust 21, 2013
Questions about this recall
Was Tacrolimus Ophthalmic, Pallimed Solutions Pharmacy, Woburn, MA recalled?
Yes. FDA published recall D-875-2013 on August 21, 2013. Reported hazard: Lack of Assurance of Sterility; FDA inspectional findings resulted in concerns associated with quality control procedures that impacted sterility assurance
What should I do if I have this product?
Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit